JP2008500279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008500279A5 JP2008500279A5 JP2006554230A JP2006554230A JP2008500279A5 JP 2008500279 A5 JP2008500279 A5 JP 2008500279A5 JP 2006554230 A JP2006554230 A JP 2006554230A JP 2006554230 A JP2006554230 A JP 2006554230A JP 2008500279 A5 JP2008500279 A5 JP 2008500279A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cells
- peptide
- cell
- endogenously
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54676404P | 2004-02-23 | 2004-02-23 | |
| US60/546,764 | 2004-02-23 | ||
| PCT/US2005/005198 WO2005082939A2 (en) | 2004-02-23 | 2005-02-17 | Anti-abeta antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008500279A JP2008500279A (ja) | 2008-01-10 |
| JP2008500279A5 true JP2008500279A5 (enExample) | 2008-03-06 |
| JP4851348B2 JP4851348B2 (ja) | 2012-01-11 |
Family
ID=34910810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006554230A Expired - Fee Related JP4851348B2 (ja) | 2004-02-23 | 2005-02-17 | 抗Ａβ抗体 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20070190046A1 (enExample) |
| EP (1) | EP1720909B1 (enExample) |
| JP (1) | JP4851348B2 (enExample) |
| KR (2) | KR20090005410A (enExample) |
| CN (1) | CN1922209B (enExample) |
| AT (1) | ATE534667T1 (enExample) |
| AU (1) | AU2005217596B2 (enExample) |
| BR (1) | BRPI0507856A (enExample) |
| CA (1) | CA2556436C (enExample) |
| CY (1) | CY1112162T1 (enExample) |
| DK (1) | DK1720909T3 (enExample) |
| EA (1) | EA009872B1 (enExample) |
| ES (1) | ES2375627T3 (enExample) |
| IL (1) | IL177611A (enExample) |
| NO (1) | NO20064239L (enExample) |
| PL (1) | PL1720909T3 (enExample) |
| PT (1) | PT1720909E (enExample) |
| SI (1) | SI1720909T1 (enExample) |
| UA (1) | UA93181C2 (enExample) |
| WO (1) | WO2005082939A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| BRPI0619249A2 (pt) | 2005-11-30 | 2011-09-20 | Abbott Lab | anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos |
| PT1976877E (pt) | 2005-11-30 | 2014-04-29 | Abbvie Inc | Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações |
| MX2008007477A (es) | 2005-12-12 | 2008-09-03 | Ac Immune Sa | Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas. |
| NZ574188A (en) | 2006-07-14 | 2012-05-25 | Ac Immune Sa | Humanized antibody against amyloid beta |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| PT2099826E (pt) | 2007-01-05 | 2014-01-09 | Univ Zuerich | Anticorpo anti-beta-amilóide e suas utilizações |
| AU2008204335B2 (en) | 2007-01-11 | 2013-06-13 | Michael Bacher | Diagnosis and treatment of Alzheimer's and other neurodementing diseases |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| EP2650308A3 (en) * | 2007-10-05 | 2014-11-12 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| EP2586795B1 (en) | 2007-10-05 | 2018-05-16 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| MX2011005481A (es) | 2008-11-25 | 2011-08-17 | Biogen Idec Inc | Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso. |
| WO2010069603A1 (en) | 2008-12-19 | 2010-06-24 | Neurimmune Therapeutics Ag | Human anti-alpha-synuclein autoantibodies |
| AR078986A1 (es) | 2009-11-12 | 2011-12-14 | Genentech Inc | Un metodo para promover la densidad de espinas dendriticas |
| EP2558494B1 (en) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta binding proteins |
| AU2011282536B2 (en) | 2010-07-30 | 2015-12-24 | Ac Immune S.A. | Safe and functional humanized anti beta-amyloid antibody |
| DK3339323T3 (da) * | 2010-08-12 | 2020-01-20 | Lilly Co Eli | Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf |
| CN105348387B (zh) | 2010-08-14 | 2020-08-25 | Abbvie 公司 | β淀粉样蛋白结合蛋白 |
| CN103796679B (zh) | 2011-06-23 | 2016-10-19 | 比奥根国际神经科学公司 | 抗-α突触核蛋白结合分子 |
| EP3970725B1 (en) | 2012-09-07 | 2025-08-20 | Massachusetts Eye & Ear Infirmary | A gamma secretase inhibitor for treating hearing loss |
| US20150209406A1 (en) | 2012-09-07 | 2015-07-30 | Massachusetts Eye And Ear Infirmary | Methods and compositions for regenerating hair cells and/or supporting cells |
| EP3683232A1 (en) | 2013-09-13 | 2020-07-22 | F. Hoffmann-La Roche AG | Methods and compositions comprising purified recombinant polypeptides |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| WO2017200762A2 (en) | 2016-05-16 | 2017-11-23 | The General Hospital Corporation | Human airway stem cells in lung epithelial engineering |
| WO2018031334A1 (en) * | 2016-08-11 | 2018-02-15 | Eli Lilly And Company | Aminothiazines and their use as bace1 inhibitors |
| AU2018321335B2 (en) | 2017-08-22 | 2025-08-14 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| TWI843040B (zh) | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| JP2025506411A (ja) | 2022-02-03 | 2025-03-11 | イーライ リリー アンド カンパニー | アルツハイマー病の診断及び治療のための局所タウイメージング |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR199901343T2 (xx) | 1996-12-23 | 1999-09-21 | Elan Pharmaceuticals, Inc. | Sikloalkil, laktam, lakton ve ilgili bile�ikler, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler. |
| US6518011B1 (en) * | 1999-01-13 | 2003-02-11 | Bristol-Myers Squibb Company | Method for screening compounds to identify beta-amyloid production modulators |
| IL151378A0 (en) * | 2000-02-24 | 2003-04-10 | Univ Washington | Humanized antibodies that sequester amyloid beta peptide |
| AU5702201A (en) * | 2000-04-13 | 2001-10-30 | Mayo Foundation | Abeta<sub>42</sub> lowering agents |
| TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| ES2318006T3 (es) * | 2001-04-30 | 2009-05-01 | Eli Lilly And Company | Anticuerpos humanizados que reconocen el peptido beta-amiloide. |
-
2005
- 2005-02-17 AU AU2005217596A patent/AU2005217596B2/en not_active Ceased
- 2005-02-17 JP JP2006554230A patent/JP4851348B2/ja not_active Expired - Fee Related
- 2005-02-17 SI SI200531422T patent/SI1720909T1/sl unknown
- 2005-02-17 EP EP05723280A patent/EP1720909B1/en not_active Expired - Lifetime
- 2005-02-17 AT AT05723280T patent/ATE534667T1/de active
- 2005-02-17 UA UAA200609258A patent/UA93181C2/ru unknown
- 2005-02-17 US US10/590,411 patent/US20070190046A1/en not_active Abandoned
- 2005-02-17 BR BRPI0507856-3A patent/BRPI0507856A/pt not_active IP Right Cessation
- 2005-02-17 KR KR1020087031635A patent/KR20090005410A/ko not_active Ceased
- 2005-02-17 EA EA200601545A patent/EA009872B1/ru not_active IP Right Cessation
- 2005-02-17 PL PL05723280T patent/PL1720909T3/pl unknown
- 2005-02-17 WO PCT/US2005/005198 patent/WO2005082939A2/en not_active Ceased
- 2005-02-17 ES ES05723280T patent/ES2375627T3/es not_active Expired - Lifetime
- 2005-02-17 KR KR1020067016812A patent/KR100889430B1/ko not_active Expired - Fee Related
- 2005-02-17 CA CA2556436A patent/CA2556436C/en not_active Expired - Fee Related
- 2005-02-17 DK DK05723280.3T patent/DK1720909T3/da active
- 2005-02-17 CN CN2005800056858A patent/CN1922209B/zh not_active Expired - Fee Related
- 2005-02-17 PT PT05723280T patent/PT1720909E/pt unknown
-
2006
- 2006-08-21 IL IL177611A patent/IL177611A/en not_active IP Right Cessation
- 2006-09-19 NO NO20064239A patent/NO20064239L/no not_active Application Discontinuation
-
2011
- 2011-12-21 CY CY20111101276T patent/CY1112162T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Diller et al. | The role of the extracellular matrix (ECM) in wound healing: a review | |
| Meier et al. | Interleukin-1 receptor antagonist modulates liver inflammation and fibrosis in mice in a model-dependent manner | |
| Joo et al. | Advanced lung organoids for respiratory system and pulmonary disease modeling | |
| Marchioni et al. | Pulmonary stretch and lung mechanotransduction: implications for progression in the fibrotic lung | |
| Sun et al. | Current perspectives on nucleus pulposus fibrosis in disc degeneration and repair | |
| Boateng et al. | Evaluation of clay-functionalized wafers and films for nicotine replacement therapy via buccal mucosa | |
| Dai et al. | Vascular remodeling: the multicellular mechanisms of pulmonary hypertension | |
| Petrini et al. | Influence of nano, micro, and macro topography of dental implant surfaces on human gingival fibroblasts | |
| Bateman et al. | Airway epithelium senescence as a driving mechanism in COPD pathogenesis | |
| WO2007077217A3 (en) | Oligopeptide-free cell culture media | |
| ATE539145T1 (de) | Verfahren zum erhalt von mesenchymalen stammzellen | |
| Loukelis et al. | Kappa-carrageenan/chitosan/gelatin scaffolds provide a biomimetic microenvironment for dentin-pulp regeneration | |
| Gehrke et al. | New implant macrogeometry to improve and accelerate the osseointegration: an in vivo experimental study | |
| Zhou et al. | Fabrication of fibrin/polyvinyl alcohol scaffolds for skin tissue engineering via emulsion templating | |
| Lettieri et al. | The plastic interplay between lung regeneration phenomena and fibrotic evolution: current challenges and novel therapeutic perspectives | |
| Syenina et al. | Th1-polarized, dengue virus-activated human mast cells induce endothelial transcriptional activation and permeability | |
| Shimizu et al. | Observation of chronic graft-versus-host disease mouse model cornea with in vivo confocal microscopy | |
| Zeissig et al. | Tumour dissemination in multiple myeloma disease progression and relapse: a potential therapeutic target in high-risk myeloma | |
| Gaddam et al. | Cystathionine-Gamma-Lyase-Derived hydrogen sulfide-regulated substance P modulates liver sieve fenestrations in Caecal ligation and puncture-induced sepsis | |
| Haas et al. | Recovery of altered diabetic myofibroblast heterogeneity and gene expression are associated with CD301b+ macrophages | |
| Volloch et al. | Next Generation Therapeutic Strategy for Treatment and Prevention of Alzheimer’s Disease and Aging-Associated Cognitive Decline: Transient, Once-in-a-Lifetime-Only Depletion of Intraneuronal Aβ (i Aβ) by Its Targeted Degradation via Augmentation of Intra-i Aβ-Cleaving Activities of BACE1 and/or BACE2 | |
| EP1687413A4 (en) | Method for differentiating mesenchymal stem cell into neural cell and pharmaceutical composition containing the neural cell for neurodegenerative disease | |
| Salim et al. | Oncostatin M receptor type II knockout mitigates inflammation and improves survival from sepsis in mice | |
| Wyganowska-Swiatkowska et al. | Atelocollagen application in human periodontal tissue treatment—A pilot study | |
| Hsiao et al. | Combined melatonin and extracorporeal shock wave therapy enhances podocyte protection and ameliorates kidney function in a diabetic nephropathy rat model |